Author:
Pourmadadi Mehrab,Mohammadzadeh Vahideh,Sadat Mohammadi Zahra,Poorkhalili Pegah,Afjoul Neda,Behzadmehr Razieh,Fathi-Karkan Sonia,Rahdar Abbas,Ghotekar Suresh
Funder
Ministry of Science Research and Technology
University of Zabol
University of Tehran
Reference103 articles.
1. An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy;Alharbi;Chem. Biol. Interact.,2022
2. Shen, Y. and W. Li, HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment. Drug design, development and therapy, 2018: p. 2285-2292.
3. Nguyen, K.-S.H. and J.W. Neal, First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics: Targets and Therapy, 2012: p. 337-345.
4. Revolutionizing anticancer drug delivery: Exploring the potential of tamoxifen-loaded nanoformulations;Sani;J. Drug Delivery Sci. Technol.,2023
5. Cisplatin-loaded superparamagnetic nanoparticles modified with PCL-PEG copolymers as a treatment of A549 lung cancer cells;Fathi Karkan;Nanomed. Res. J.,2019
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献